RECALL OF ANEMIA DRUG OMONTYS
Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP
By Thamanna Hussain
The U.S. Food and Drug Administration alerted health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by U.S.-based Affymax Inc. and Japan's Takeda Pharmaceutical Co. The FDA also said that it had received 19 reports of anaphylaxis from dialysis centers in the United States. Our firm is no stranger to litigation against Takeda. We are currently litigating for plaintiffs who sadly got bladder cancer after taking the dangerous drug Actos.
Omontys is a drug which is used to treat anemia in adult dialysis patients and has resulted in serious allergic reactions, known as anaphylaxis. The voluntary recall is due to severe hypersensitivity reactions, and reports of anaphylaxis, a serious and life-threatening allergic reaction. The agency is investigating the products and facilities related to the recall and will provide updates once it receives more information.
If you or loved one suffered a serious reaction or death following the use of Omontys, please contact our law firm.